Interstitial Lung Disease: From Initial Investigations to Treatments, Shared Care and Beyond
Interstitial lung disease (ILD) is characterised by progressive scarring of the lungs, leading to respiratory failure and a high symptom burden. High resolution CT of the chest with prone views is the investigation of choice when assessing for ILD. A low threshold should be applied for investigating patients presenting with persistent cough or dyspnoea with risk factors for ILD including connective tissue disease, occupational exposure, certain drug therapies and a family history. Antifibrotic therapy (nintedanib) for any patients with ILD who exhibit progressive fibrosing features offers an opportunity for improved patient outcomes with early disease identification and access to respiratory services. Blood monitoring is required lifelong for patients taking antifibrotics or steroid-sparing ILD treatments.
Modern Medicine – Issue 1, 2025
